MYELOPROLIFERATIVE DISORDERS

This study tests whether combining three drugs—tacrolimus, methotrexate, and a new dosing schedule of anti-thymocyte globulin—can prevent acute graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers like leukemia. About 29 adults aged 18-60 w…

This early-stage study tests an experimental drug called JNJ-88549968 in people with certain blood cancers (myelofibrosis or essential thrombocythemia) that have a specific CALR gene mutation. The drug is a bispecific antibody designed to redirect the body's immune T-cells to att…

This early-phase trial tests whether specially trained natural killer (NK) cells can safely prevent blood cancers like leukemia from coming back after a stem cell transplant. About 15 adults with high-risk disease will receive an infusion of these cells plus a supportive drug. Th…

This study tests a two-step method of giving an anti-rejection drug (ATG) along with standard medications to prevent severe graft-versus-host disease (GVHD) in people with blood cancers receiving a stem cell transplant. About 56 adults aged 18-75 will participate. The goal is to …

This study is testing a new platform that uses advanced testing to better understand different types of cancer, including leukemia, myeloma, and solid tumors. The goal is to see if this platform can change the recommended treatment for patients, making it more personalized. About…

This study tests whether 30 adults with myeloproliferative neoplasms (a type of blood disorder) can stick with a 12-week program that teaches healthy eating and physical activity. The main goal is to see if at least 70% of participants complete 9 weeks of the program. If successf…

This study is looking for better ways to predict blood clots in people with myeloproliferative neoplasms (MPNs), a group of blood cancers. Researchers will measure specific markers in the blood of 300 participants to see if these markers can identify who is at higher risk for clo…

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This study looks at blood cancer cells from 250 patients to understand which drugs might work best. Researchers will test many approved and experimental drugs on these cells in the lab. The goal is to find new treatment targets and match them to each patient's cancer type. This i…

This study is collecting blood, bone marrow, and tissue samples from over 1,000 people with blood cancers like leukemia and myeloma. Researchers will use advanced lab techniques to find unique markers (biomarkers) for each cancer type. The goal is to better understand these disea…

This study follows 5,000 adults with myeloproliferative neoplasms (MPNs) — rare blood cancers — to understand how symptoms change and how the disease progresses over years. Participants share their health records, insurance data, and regular surveys about how they feel. No new tr…